Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial

Año publicación: 2025

Subir documento: https://drive.google.com/file/d/14P2YFFNfVSQRxcxYaUGbJkrFJkhqCDBT/view?usp=sharing

Nombre investigadores: Frederick J Raal, Vimal Mehta, Meral Kayikcioglu, Dirk Blom, Preeti Gupta, Avishay Elis, Traci Turner, Chris Daniels, Jeffrey Vest, Tracy Mitchell, Kate Caldwell, El Mustapha Bahassi, David Kallend, Evan A Stein